After bursting onto the scene several years ago with considerable fanfare, much of the hype about cannabis stocks has quietly died down, and ...

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

This success has seen other traditional pharma companies, such as Otsuka Pharmaceutical ... to patients. With GW Pharma previously achieving approval for a cannabis-based treatment, despite ...

The cannabis-derived compound cannabidiol (CBD) is gaining traction as a treatment for a broad range of conditions, but it's ...

Today’s regulatory gaps and health concerns about CBD reflect those of the 19th century, when cannabis was first commercialised by the food industry.

Scientists have come up with an innovative solution to improve the effectiveness of cannabidiol to treat epilepsy, multiple sclerosis and other neurodegenerative diseases.

Mar. 18, 2025 — A research team has found that lecanemab was probably less effective in females than males in its Phase 3 trial. However, there was insufficient evidence to say the drug was ...

FILE PHOTO: Logo and flags of Bayer AG are pictured outside a plant of the German pharmaceutical and chemical maker in Wuppertal, Germany August 9, 2019. REUTERS/Wolfgang Rattay/File Photo Bayer ...

Alnylam jumps as expanded US approval for heart disease drug fuels growth prospects Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its ...

Forbes contributors publish independent expert analyses and insights. Sarah Sinclair is an award-winning journalist covering cannabis.

Syqe Medical Receives Regulatory Approval to Release World’s First Drug Delivery Device for Precise Dosing of Cannabis Leading pharma-tech company launches its first-in-class, pharmaceutical ...

After hours: March 21 at 7:32:40 PM EDT Loading Chart for JAZZ ...